KemPharm Stock News

KemPharm, Inc. (NASDAQ:KMPH) CEO Travis C. Mickle bought 2,250 shares of the stock in a transaction on Thursday, November 18th. The shares were purchased at an average price of $8.23 per share, with a total value of $18,517.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. []

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Equities analysts expect KemPharm, Inc. (NASDAQ:KMPH) to report ($0.06) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for KemPharms earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). The firm is expected to issue its next earnings results on Thursday, March 10th. On []

KemPharm (NASDAQ:KMPH)s stock had its hold rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Friday, Price Targets.com reports. They presently have a $10.00 target price on the specialty pharmaceutical companys stock. HC Wainwrights price objective suggests a potential upside of 9.65% from the stocks previous close. Separately, Zacks []

KemPharm's (KMPH) CEO Travis Mickle on Q3 2021 Results - Earnings Call Transcript

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021, 4:30 p.m. ET

Trading to commence effective with the open of business on October 19, 2021

CELEBRATION, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announc

CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announc

CELEBRATION, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced toda

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2021 Results - Earnings Call Transcript

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET

CELEBRATION, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced

Investors reacted negatively to the company's warrant exchange.